We have shown that proteasomal inhibition activated IRE1α to recruit TRAF2 and activate NF‐κB to transcribe inflammatory cytokine and chemokine, thus creating a favorable tumor microenvironment for immunotherapy. The gene discussed is ERN1; the disease is neoplasm.